binding affinity News and Research

RSS

SARS-CoV-1 and SARS-CoV-2 spike proteins utilize different mechanisms to bind to ACE2

Researchers apply computational approaches to study the binding mechanisms of the SARS-CoV-2 and SARS-CoV spike proteins to the ACE2 receptor.

11 Dec 2022

Researchers design novel compounds with potential as drug treatments for COVID-19

The ongoing COVID-19 pandemic, caused by the SARS-CoV-2 virus, has been devastating the entire world. While the vaccination program is advancing, drug treatments for COVID-19 are still highly important for those who become infected.

9 Dec 2022

Characterization of SARS-CoV-2 Omicron BQ.1.1

Researchers characterized the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BQ.1.1 sub-variant.

9 Dec 2022

Novel prefusion S antigen designed by the mutation of the SARS-CoV-2 Spike protein’s trimeric structure

Researchers mutated the SARS-CoV-2 spike protein's trimeric structure to design a novel prefusion S antigen, S2D14.

1 Dec 2022

Fingerprint-embedding framework can help find novel drug candidates

Researchers have developed a new computer framework that holds promise in the work to discover new drugs. Their framework uses an artificial intelligence method called convolutional neural network to provide global information about potential novel drug candidates.

30 Nov 2022

The antibody resistance profile and viral receptor binding affinity of SARS-CoV-2 Omicron BQ.1, BQ.1.1, XBB, and XBB.1 subvariants

Researchers investigated the neutralizing antibody titers against the newly emergent BQ.1, BQ.1.1, XBB, and XBB.1 SARS-CoV-2 Omicron subvariants using sera from individuals with primary and booster COVID-19 vaccinations and previous SARS-CoV-2 infections.

30 Nov 2022

Isolated monoclonal antibodies targeting SARS-CoV-2 S1/S2 cleavage effective against Delta and Omicron

Isolated monoclonal antibodies neutralize SARS-CoV-2 Delta and Omicron variants.

28 Nov 2022

Glycan signatures in rheumatic diseases and their associated functional implications

A new paper examines the understanding of glycosylation in an array of rheumatic diseases and indicates the potential for therapeutic interventions using the same mechanism.

28 Nov 2022

Memory B and T cells responses differ when induced by SARS-CoV-2 infections or booster vaccinations

In a recent study published in The Journal of Immunology, a team of researchers from Japan examined the memory B and T cell responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein after the booster dose of the coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine BNT162b2.

27 Nov 2022

Development of a potent, broadly protective vaccine against all SARS-CoV-2 variants

In a recent study published in the journal npj Vaccines, researchers in China designed, produced, and evaluated the neutralization efficacy of a recombinant coronavirus disease 2019 (COVID-19) vaccine containing four hot-spot substitution mutations based on a prefusion-stabilized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S) trimer.

15 Nov 2022

Researchers discover new antiviral compounds derived from two Korean native plants

Codonopsis lanceolata, more commonly referred to as "deodeok", is used as a medicinal herb in South Korea.

11 Nov 2022

Novel monoclonal antibodies NA8 and NE12 can neutralize most SARS-CoV-2 variants and Omicron subvariants

Researchers generated and characterized two monoclonal antibodies (NA8 and NE12) that target the receptor binding domain of the SARS-CoV-2 spike protein, and exhibit neutralizing activity against major SARS-CoV-2 variants of concern.

3 Nov 2022

What is the role of cyclophilin-A in alleviating SARS-CoV-2 infections?

A new study aimed to analyze the molecular interactions between the hCypA protein and the SARS-CoV-2 variants to determine the impact of variants on the blocking and binding potential of the hCypA–S protein complex with the ACE2 receptor.

2 Nov 2022

How does imprinted SARS-CoV-2 humoral immunity drive convergent Omicron evolution?

Researchers examined how imprinted SARS-CoV-2 humoral immunity drives convergent evolution in continuously emerging Omicron subvariants.

2 Nov 2022

Scientists computationally restore the potency of an antibody against SARS-CoV-2 Omicron subvariants

A team of researchers from the United States computationally modified the COV2-2130 monoclonal antibody to restore its neutralizing ability against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants, while retaining efficacy against the Delta and wild-type strains.

27 Oct 2022

binding affinity News and Research

SARS-CoV-1 and SARS-CoV-2 spike proteins utilize different mechanisms to bind to ACE2

Researchers design novel compounds with potential as drug treatments for COVID-19

Characterization of SARS-CoV-2 Omicron BQ.1.1

Novel prefusion S antigen designed by the mutation of the SARS-CoV-2 Spike protein’s trimeric structure

Fingerprint-embedding framework can help find novel drug candidates

The antibody resistance profile and viral receptor binding affinity of SARS-CoV-2 Omicron BQ.1, BQ.1.1, XBB, and XBB.1 subvariants

Isolated monoclonal antibodies targeting SARS-CoV-2 S1/S2 cleavage effective against Delta and Omicron

Glycan signatures in rheumatic diseases and their associated functional implications

Memory B and T cells responses differ when induced by SARS-CoV-2 infections or booster vaccinations

Development of a potent, broadly protective vaccine against all SARS-CoV-2 variants

Researchers discover new antiviral compounds derived from two Korean native plants

Novel monoclonal antibodies NA8 and NE12 can neutralize most SARS-CoV-2 variants and Omicron subvariants

What is the role of cyclophilin-A in alleviating SARS-CoV-2 infections?

How does imprinted SARS-CoV-2 humoral immunity drive convergent Omicron evolution?

Scientists computationally restore the potency of an antibody against SARS-CoV-2 Omicron subvariants

The impact of existing and theoretical mutations on SARS-CoV-2 CD8+ T cell targets

Bovine ultralong complementarity-determining region H3 found to cross-react with sarbecoviruses

What is the efficacy of mulberry component Kuwanon C against COVID-19?

The Black Death may have influenced the evolution of genes involved in immune responses against pathogens

Antibody-mediated protection against symptomatic COVID achieved at low serum neutralizing titers

Binding kinetics in drug discovery eBook eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News